Potential role of CXCR4 in trastuzumab resistance in breast cancer patients-Reference-Cited by-同舟云学术

Potential role of CXCR4 in trastuzumab resistance in breast cancer patients

Published:2022-11 Issue:11 Volume:1868 Page:166520
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Kotb Ranim M.,Ibrahim Safinaz S.,Mostafa Osama M.,Shahin Nancy N.^ORCID

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference48 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;Cancer J. Clin.,2021

2. Adjuvant HER2-targeted therapy update in breast cancer: escalation and De-escalation of therapy;Murthy;Curr. Breast Cancer Rep.,2018

3. Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis;Debiasi;Front. Oncol.,2018

4. The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: a meta-analysis;Zhang;Medicine (Baltimore),2019

5. Resistance to trastuzumab in breast cancer;Pohlmann;Clin. Cancer Res.,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemokines as Prognostic Factor in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2024-05-15

2. RNA-binding proteins in breast cancer: Biological implications and therapeutic opportunities;Critical Reviews in Oncology/Hematology;2024-03

3. The role of PKC and PKD in CXCL12 and CXCL13 directed malignant melanoma and acute monocytic leukemic cancer cell migration;Cellular Signalling;2024-01

4. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment;Breast Cancer Research;2023-06-06

5. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment;2023-02-14